BENITEC BIOPHARMA LIMITED ASX Appendix 4C
Quarterly Cash Flow Report
for the quarter ended 30 September 2014
Sydney, 31 October 2014:Benitec Biopharma Limited (ASX: BLT, OTC: BTEBY) attaches the Company's Appendix 4C Quarterly Cash Flow Report for the period ended 30 September 2014.
Benitec held $29.5 million in cash at 30 September 2014, compared to $31.3 million at 30 June
2014. Net operating cash flow for the quarter was ($2.0) million, and included scientific and
business development expenditure of $1.1 million.
For further information, please contact the persons noted below, or visit the Benitec website
at www.benitec.com.
Company Investor relations
Carl Stubbings
Chief Business Officer Tel: +61 (2) 9555 6986
Email: cstubbings@benitec.com
About Benitec Biopharma Limited:
Jane Lowe
Buchan Consulting Tel: +61 (2) 9237 2807
Email: jlowe@buchanwe.com.au
Benitec Biopharma Limited is an ASX-‐listed biotechnology company (ASX: BLT, OTC: BTEBY) based in Sydney, Australia. The company has a pipeline of in-‐house and partnered therapeutic programs based on its patented gene-‐silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-‐threatening human conditions such as Hepatitis C, Hepatitis B, wet age-‐related macular degeneration, cancer-‐associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at www.benitec.com. A glossary of terms used in relation to ddRNAi is available via the following link: http://www.benitec.com/glossary.php.
Appendix 4C Quarterly report for entities
admitted on the basis of commitments
Rule 4.7B
Appendix 4C Quarterly report for entities admitted on the basis of commitmentsIntroduced 31/3/2000. Amended 30/9/2001, 24/10/2005.
Name of entity
BENITEC BIOPHARMA LIMITED
ABN Quarter ended ("current quarter")
64 068 943 662 30 September 2014
Consolidated statement of cash flows
Cash flows related to operating activities
1.1 Receipts from customers
Research and Development Grants
1.2 Payments for (a) staff costs
(b) advertising and marketing (c) research and development (d) leased assets
(e) other working capital
1.3 Dividends received
1.4 Interest and other items of a similar nature received
1.5 Interest and other costs of finance paid
1.6 Income taxes refunded/(paid)
1.7 Other (provide details if material) Income tax refund
Net operating cash flows
+ See chapter 19 for defined terms.
Appendix 4C Page 1
Appendix 4C
Quarterly report for entities
admitted on the basis of commitments
Current quarter $A'000 | Year to date (3 months) $A'000 | |
1.8 Net operating cash flows (carried forward) | (2,008) | (2,008) |
Cash flows related to investing activities 1.9 Payment for acquisition of: (a) businesses (item 5) (b) equity investments (c) intellectual property (d) physical non-current assets (e) other non-current assets 1.10 Proceeds from disposal of: (a) businesses (item 5) (b) equity investments (c) intellectual property (d) physical non-current assets (e) other non-current assets 1.11 Loans to other entities 1.12 Loans repaid by other entities 1.13 Other (provide details if material) Net investing cash flows 1.14 Total operating and investing cash flows | - - - - - - - - - - - - - | - - - - - - - - - - - - - |
Cash flows related to investing activities 1.9 Payment for acquisition of: (a) businesses (item 5) (b) equity investments (c) intellectual property (d) physical non-current assets (e) other non-current assets 1.10 Proceeds from disposal of: (a) businesses (item 5) (b) equity investments (c) intellectual property (d) physical non-current assets (e) other non-current assets 1.11 Loans to other entities 1.12 Loans repaid by other entities 1.13 Other (provide details if material) Net investing cash flows 1.14 Total operating and investing cash flows | - | - |
Cash flows related to investing activities 1.9 Payment for acquisition of: (a) businesses (item 5) (b) equity investments (c) intellectual property (d) physical non-current assets (e) other non-current assets 1.10 Proceeds from disposal of: (a) businesses (item 5) (b) equity investments (c) intellectual property (d) physical non-current assets (e) other non-current assets 1.11 Loans to other entities 1.12 Loans repaid by other entities 1.13 Other (provide details if material) Net investing cash flows 1.14 Total operating and investing cash flows | (2,008) | (2,008) |
Cash flows related to financing activities 1.15 Proceeds from issues of shares, options, etc. 1.16 Proceeds from sale of forfeited shares 1.17 Proceeds from borrowings 1.18 Repayment of borrowings 1.19 Dividends paid 1.20 Other Net financing cash flows | 170 - - - - - | 170 - - - - - |
Cash flows related to financing activities 1.15 Proceeds from issues of shares, options, etc. 1.16 Proceeds from sale of forfeited shares 1.17 Proceeds from borrowings 1.18 Repayment of borrowings 1.19 Dividends paid 1.20 Other Net financing cash flows | 170 | 170 |
Net increase (decrease) in cash held 1.21 Cash at beginning of quarter/year to date 1.22 Exchange rate adjustments 1.23 Cash at end of quarter | (1,838) 31,351 - | (1,838) 31,351 - |
Net increase (decrease) in cash held 1.21 Cash at beginning of quarter/year to date 1.22 Exchange rate adjustments 1.23 Cash at end of quarter | 29,513 | 29,513 |
+ See chapter 19 for defined terms.
Appendix 4C Page 2
Appendix 4C Quarterly report for entities
admitted on the basis of commitments
Payments to directors of the entity and associates of the directors
Payments to related entities of the entity and associates of the related entities
1.24 Aggregate amount of payments to the parties included in item 1.2
Current quarter
$A'000
123
1.25 Aggregate amount of loans to the parties included in item 1.11 -
1.26 Explanation necessary for an understanding of the transactions
Payments related to directors' fees ($75k) and legal services ($48k)
Non-cash financing and investing activities
2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows
None
2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest
None
+ See chapter 19 for defined terms.
Appendix 4C Page 3
Appendix 4C
Quarterly report for entities
admitted on the basis of commitments
Financing facilities available
Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).
3.1 Loan facilities
3.2 Credit standby arrangements
Reconciliation of cash
Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.
Acquisitions and disposals of business entities
5.1 Name of entity
5.2 Place of incorporation or registration
5.3 Consideration for acquisition or disposal
5.4 Total net assets
5.5 Nature of business
+ See chapter 19 for defined terms.
Appendix 4C Page 4
Compliance statement
Appendix 4C Quarterly report for entities
admitted on the basis of commitments
1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
2 This statement does give a true and fair view of the matters disclosed.
Sign here: | ............................................................ | Date: 31 October 2014 |
Print name: | (Company Secretary) Greg West |
+ See chapter 19 for defined terms.
Appendix 4C Page 5
|
distributed by
|
